Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
In Vitro Diagnostics Cancer Clinical Trials

Inivata Continues Trials Of Its Liquid Biopsy Platform

  • News

Executive Summary

The partnership with the Princess Margaret Cancer Center will support two studies of liquid biopsy testing for lung cancer.

You may also be interested in...



NeoGenomics Bolsters Liquid Diagnostics Portfolio By Acquiring Inivata

Inivata will remain a separate liquid biopsy division alongside NeoGenomics’ growing clinical, pharma and informatics divisions.

Seeing The Wood From The Shrubs: Azalea Begins Tests Of Its Smart Contact Lens

The Belgian start-up is developing a scleral contact lens with an inbuilt LCD screen capable of filtering light – offering a non-surgical solution to a variety of ophthalmic conditions.

Octave Biosciences Takes It Up Another Semitone With Michael J Fox Foundation Grant

The diagnostics company has secured $10m from the foundation to develop a biomarker test for Parkinson’s disease.

Table

View full table

Topics

Related Companies

Tags:
In Vitro Diagnostics Cancer Clinical Trials
Latest Headlines

Mosie Baby First To Win FDA Clearance For At-Home DYI Artificial Insemination Kit

“We’re A Pain-Management Company.” Nevro Adds SI Joint Surgery To SCS Business

MDR Changes Aren’t A ‘Catalyst’ For Medtech Investments In Ireland

eSTAR Now Open For PMA Submissions

See All
UsernamePublicRestriction

Register

MT144604

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By